Innovation Pharmaceuticals Inc (IPIX)

[KMBJN]

I couldn't find anything when I looked in Feb - March.

Look under PMX-30063 William DeGrado (now at UCSF) and Scott (now at Fox Chase).

The February PR may give you the best explanation you seem to be looking for:

https://finance.yahoo.com/news/innovation-pharmaceuticals-exploring-lead-defensin-161947696.html

Despite outbreaks of zoonotic coronaviruses (those that jumped from animals to humans) like COVID-19, MERS-Cov and SARS-CoV—cumulatively responsible for thousands of deaths— scientists have been challenged to develop effective treatments given the latest current threat usually subsides before a drug or vaccine can be adequately tested for safety and efficacy.

To that point, there is a movement within academia and regulatory bodies towards testing the antiviral potential of late-phase and approved drugs. These drugs have more established pharmacodynamic and pharmacokinetic profiles, thereby offering the opportunity to greatly shorten the development timeframe should they prove beneficial in treating coronaviruses.

This is exactly where Brilacidin fits in into the emerging Coronavirus threat—a promising small molecule in late-phase development worthy of further evaluation as to its antiviral properties.

Brilacidin already has demonstrated broad and robust antibacterial, anti-inflammatory and immunomodulatory properties in multiple FDA clinical trials. Pre-clinical research also supports Brilacidin’s antiviral properties based on work by conducted by Dr. William DeGrado (UCSF) and Dr. Richard Scott (Fox Chase).

Brilacidin and other defensin mimetics similar in structure to Brilacidin have been tested against enveloped viruses with moderate activity noted from the outset. To date, Brilacidin has not been tested specifically against Coronavirus (an enveloped positive stranded RNA virus). But the scientists who conducted preliminary research are optimistic about the multi-tiered advantages of Brilacidin to elicit a response when accompanied by drug optimization, formulation and delivery work.

I couldn't find anything much about the highlighted parts.

I wonder what they presented here at antiviral conference?

https://www.biospace.com/article/releases/polymedix-inc-to-present-at-22nd-b-international-conference-on-antiviral-research-icar-b-/


They suspected it could have antiviral properties, and we were fortunate for that to be the case. Could have just been "Hey let's check everything we can" that the biotech/drug world was doing, and I'm sure a few people thought it could be something worthy to pursue. I think these were very few people, so thanks and congratulations to whoever they are! Certainly was worth it to try on someone else's dime. It just took a LOT longer that way.

I won't call it "dumb luck" anymore since it upset so many people. How does "inspired confidence" and "good fortune" sound?

I consider my own recent biotech investment success to be dumb luck however, so maybe that's why I referred to it as that! I invested in biotech stocks for non-covid reasons, and 6 out of the 8 suddenly have potential Covid solutions (repurposing existing drugs or quickly designing anti-SARS2 drug or vaccine based on a platform technology) that have given them new life or an amazing boost at least. I count IPIX in that category.